Committed to innovation, Da Volterra develops microbiota protecting therapies as well as tools intended to harness potential to help prevent and cure human diseases.
Prevention of C. difficile infection in patients with a history of CDI
Prevention of C. difficile infection & acute graft-versus-host disease (GvHD) in patients with hematologic malignancies
Add-on therapy to preserve the efficacy of immune checkpoint inhibitors (ICI) in cancer patients
Reduction of severe diarrheas (Grade 3-4) and other consequences due to chemotherapy-induced disruption of the microbiota
Microbiome Discovery Platform
New microbiome diagnostic tests, predictive of clinical manifestations of dysbiosis
Novel microbiome-targeted protective and interventional therapies
Over the years since inception, we have gathered a unique in-house expertise on the intestinal microbiota and its links to the different body functions, antibacterial drugs and other drugs disrupting the microbiota as well as drug delivery technologies.